Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a few doses of ketamine help both depression and alcohol addiction?

NCT ID NCT06090422

Disease control Sponsor: University Hospital of North Norway Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether ketamine, given as four intravenous infusions over two weeks, can reduce depression and alcohol cravings in adults who have both conditions. Participants are already in inpatient addiction therapy and are randomly assigned to receive either ketamine or a low-dose sedative (midazolam) as a comparison. The trial tracks changes in depression severity and alcohol craving over six months to see if ketamine offers added benefit beyond standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ketamine hydrochloride
What this could lead to
If successful, this could point toward a new treatment approach for people struggling with both depression and alcohol use disorder.
What could go wrong
This is an early-phase trial with only 34 participants, so results may not apply to everyone. Ketamine can cause side effects like dissociation and blood pressure changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Please contact the project team for a full and detailed list of inclusion/exclusion criteria Inclusion Criteria: * Currently abstinent from alcohol * At least moderate depression without psychotic features * Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20 * Alcohol dependence * Admitted for inpatient addiction therapy at University Hospital of North Norway Exclusion Criteria: * Intoxicated or in significant withdrawal from alcohol or drug use * Not able to give adequate informed consent * Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder * Current or historical diagnosis of schizophrenia in a first degree relative * Cardiovascular conditions: recent stroke (\< 1 year from informed consent), recent myocardial infarction (\< 1 year from informed consent), uncontrolled hypertension (\>150/100 mm Hg) or recent arrhythmia (\< 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital) * Liver (Child-Pughs Class C) or kidney (Creatinin clearance \< 30 mL/min) failure * Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV) * Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and/or Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher) * Previous anaphylactic reaction to ketamine or midazolam * Illegal use of ketamine the last 6 months * Pregnancy or breastfeeding * Current or suspected increased intracranial pressure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alcohol use disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alcohol abuse Behavior, Addictive Depression depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alcohol use disorder Depression

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Addiction, University Hospital of North Norway

    RECRUITING

    Tromsø, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.